Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Disparities in Results of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With Anti-PD-1/Anti-PD-L1 Immunotherapy in a Community Oncology Setting

NCT05364086 is registered in ClinicalTrials.gov with University of Rochester NCORP Research Base as lead sponsor.

NCT NCT05364086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05364086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Disparities in Results of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With Anti-PD-1/Anti-PD-L1 Immunotherapy in a Community Oncology Setting
Lead sponsor
University of Rochester NCORP Research Base
Phase
Observational
Overall status
Active, not recruiting
Start date
April 26, 2022
Completion date
January 31, 2030
Enrollment
2,100 (estimated)
Sites
259

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic and lymphoid cell neoplasm, malignant solid neoplasm